Qubigen
June 16, 2025
Company Presentation
Tools/Drug Development Support Tech
Qubigen is an exciting new venture that combines Federated AI technology, quantum chemistry and AI drug design capabilities. Qubigen’s mission is to create the largest global federated proprietary dataset and computational toolbox for AI driven drug design.
Federated AI enables a global ‘collaborative-first’ approach by significantly increasing the access to health technology to a broader range of collaborators. Bringing together Data Access partners, we are helping to crack the world's toughest diseases by fostering a collaborative federated data approach for new medicines that no single company could develop on their own.
Company HQ City:
Melbourne
Company HQ State:
Victoria
Company HQ Country:
Australia
Year Founded:
2024
Lead Product in Development:
Federated AI for Drug Design (FedAID)
CEO
Jonathan Hall
Development Phase of Lead Product
Other/Not Applicable
When you expect your next catalyst update?
While we're targeting a Series A raise in 6–8 months, we’re currently seeking $3M in bridge capital to validate our fully productized system through a final set of case studies. We've already completed several initial studies and secured collaborations with a few major research institutes. This next phase will allow us to further demonstrate the scalability and impact of our platform across a broader range of real-world applications.
What is your next catalyst (value inflection) update?
June 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}